TGF-Beta Bone Fragility at the Tumor-Bone Interface in Myeloma

骨髓瘤肿瘤-骨界面处的 TGF-β 骨脆性

• 批准号: 7784482
• 负责人: GREGORY R MUNDY
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2013-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7784482
• 关键词: Address; African American; Anatomy; Antibodies; Biomechanics; Bone Diseases; Bone Marrow; Bone Resorption; Bone neoplasms; Bortezomib; Cells; Characteristics; Clinical Research; Data; Disease; Disease model; Engineering; Environment; Event; Fracture; Genetic; Goals; Growth; Health; Healthcare; Impairment; In Vitro; Institutes; Intractable Pain; Knock-out; Knockout Mice; Lead; Ligands; Lytic Metastatic Lesion; Malignant Neoplasms; Maps; Marrow; Measurement; Measures; Mediating; Minerals; Modeling; Monoclonal Antibodies; Multiple Myeloma; Mus; Mutation; Osteoblasts; Osteolysis; Patients; Pharmacotherapy; Phase; Phosphotransferases; Population; Pre-Clinical Model; Predisposition; Property; Proteasome Inhibitor; Protocols documentation; Quality of life; Raman Spectrum Analysis; Resistance; Role; Schools; Serum; Signal Transduction; Site; Skeleton; Staging; Stromal Cells; Structure; Tail; Techniques; Technology; Testing; Therapeutic; Time; Tissues; Transforming Growth Factor beta; Tumor Burden; Veins; Veterans; Zoledronic Acid; abstracting; base; bisphosphonate; bone; bone geometry; bone growth factor; bone quality; bone toughness; density; design; digital; effective therapy; improved; inhibitor/antagonist; male; middle age; mouse model; neoplastic cell; neutralizing monoclonal antibodies; normal aging; optical imaging; osteoblast differentiation; preclinical study; receptor; research study; skeletal; small molecule; submicron; tumor growth